MDxHealth Bilan de santé

Santé financière contrôle des critères 4/6

MDxHealth possède un total de capitaux propres de $17.8M et une dette totale de $36.0M, ce qui porte son ratio d'endettement à 201.8%. Son actif total et son passif total sont $135.7M et de $117.9M.

Informations clés

201.8%

Ratio d'endettement

US$36.01m

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$32.71m
Fonds propres	US$17.84m
Total du passif	US$117.89m
Total des actifs	US$135.73m

Mises à jour récentes de la santé financière

Recent updates

Why Investors Shouldn't Be Surprised By MDxHealth SA's (EBR:MDXH) 29% Share Price Plunge

Oct 05

MDxHealth (EBR:MDXH) Has Debt But No Earnings; Should You Worry?

Aug 29

MDxHealth (EBR:MDXH) Is Carrying A Fair Bit Of Debt

Apr 21

Is MDxHealth (EBR:MDXH) Using Debt In A Risky Way?

May 05

Here's Why MDxHealth (EBR:MDXH) Can Manage Its Debt Despite Losing Money

Nov 08

MDxHealth (EBR:MDXH) Has Debt But No Earnings; Should You Worry?

Mar 23

MDxHealth's (EBR:MDXH) Stock Price Has Reduced 75% In The Past Five Years

Jan 29

Is MDxHealth (EBR:MDXH) Weighed On By Its Debt Load?

Nov 27

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de MDXH ( $45.6M ) dépassent ses passifs à court terme ( $18.8M ).

Passif à long terme: Les actifs à court terme de MDXH ( $45.6M ) ne couvrent pas ses passifs à long terme ( $99.0M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de MDXH ( 18.5% ) est considéré comme satisfaisant.

Réduire la dette: Le ratio d'endettement de MDXH est passé de 0.3% à 201.8% au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: MDXH dispose d'une piste de trésorerie suffisante pour plus d'un an sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: MDXH dispose d'une marge de trésorerie suffisante pour plus de 3 ans si le flux de trésorerie disponible continue de diminuer à un taux historique de 6.9 % chaque année

MDxHealth Bilan de santé

Santé financière contrôle des critères 4/6

Informations clés

Mises à jour récentes de la santé financière

MDxHealth SA Shares No Longer Be Listed and Traded on Euronext Brussels, Effective as of Close of Trading on Euronext Brussels on December 15, 2023

MDxHealth SA Shares No Longer Be Listed and Traded on Euronext Brussels, Effective as of Close of Trading on Euronext Brussels on December 15, 2023

MDxHealth (EBR:MDXH) Has Debt But No Earnings; Should You Worry?

MDxHealth (EBR:MDXH) Is Carrying A Fair Bit Of Debt

Is MDxHealth (EBR:MDXH) Using Debt In A Risky Way?

Here's Why MDxHealth (EBR:MDXH) Can Manage Its Debt Despite Losing Money

Recent updates

MDxHealth SA Provides Revenue Guidance for the Year 2025

MDxHealth SA has filed a Follow-on Equity Offering in the amount of $40 million.

Mdxhealth SA Raises Earnings Guidance for the Year 2024

MDxHealth SA Revises Earnings Guidance for the Year 2024

MDxHealth SA has filed a Follow-on Equity Offering in the amount of $50 million.

Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering

MDxHealth SA Maintains Earnings Guidance for the Year 2024

MDxHealth SA Announces Jan Pensaert Steps Down from its Board of Directors

MDxHealth SA Provides Earnings Guidance for the Fourth Quarter and Full Year 2023 and Year 2024

MDxHealth SA to Report Q1, 2024 Results on May 08, 2024

MDxHealth SA Shares No Longer Be Listed and Traded on Euronext Brussels, Effective as of Close of Trading on Euronext Brussels on December 15, 2023

MDxHealth SA Shares No Longer Be Listed and Traded on Euronext Brussels, Effective as of Close of Trading on Euronext Brussels on December 15, 2023

New minor risk - Profitability

MDxHealth SA Provides Earnings Guidance for the Year 2023

MDxHealth SA Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Why Investors Shouldn't Be Surprised By MDxHealth SA's (EBR:MDXH) 29% Share Price Plunge

MDxHealth SA to Report Q3, 2023 Results on Oct 09, 2023

Consensus EPS estimates fall by 10%, revenue upgraded

MDxHealth (EBR:MDXH) Has Debt But No Earnings; Should You Worry?

New major risk - Share price stability

MDxHealth SA Reaffirms Revenue Guidance for the Year 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

MDxHealth (EBR:MDXH) Is Carrying A Fair Bit Of Debt

Full year 2022 earnings released: US$0.28 loss per share (vs US$0.24 loss in FY 2021)

Third quarter 2022 earnings released: US$0.078 loss per share (vs US$0.06 loss in 3Q 2021)

MDxHealth SA to Report First Half, 2023 Results on Aug 23, 2023

MDxHealth SA Provides Revenue Guidance for the Fiscal Year 2023

MDxHealth SA Revises Revenue Guidance for the Fiscal Year 2022

Price target increased to €1.20

MDxHealth SA Reaffirms Revenue Guidance for the Year 2022

Third quarter 2022 earnings released: US$0.05 loss per share (vs US$0.059 loss in 3Q 2021)

Second quarter 2022 earnings released: US$0.072 loss per share (vs US$0.06 loss in 2Q 2021)

MDxHealth SA (ENXTBR:MDXH) acquired Oncotype DX GPS Prostate Cancer Business from Exact Sciences Corporation (NasdaqCM:EXAS) for $100 million.

MDxHealth SA (ENXTBR:MDXH) acquired Oncotype DX GPS Prostate Cancer Business from Exact Sciences Corporation (NasdaqCM:EXAS) for $100 million.

Mdxhealth Sa Announces Resignation of Rudi Mariën as Non-Executive Director

Palmetto GBA’s MolDX Issues Foundational LCD Covering the Indication for SelectMDx for Prostate Cancer

Is MDxHealth (EBR:MDXH) Using Debt In A Risky Way?

Full year 2021 earnings released

Price target increased to €1.20

MDxHealth SA Provides Revenue Guidance for the Full Year 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Here's Why MDxHealth (EBR:MDXH) Can Manage Its Debt Despite Losing Money

First half 2021 earnings released: US$0.12 loss per share (vs US$0.18 loss in 1H 2020)

MDxHealth (EBR:MDXH) Has Debt But No Earnings; Should You Worry?

Full year 2020 earnings released: US$0.34 loss per share (vs US$0.69 loss in FY 2019)

Revenue misses expectations

MDxHealth SA to Report Fiscal Year 2020 Results on Apr 28, 2021

MDxHealth SA to Report Fiscal Year 2020 Results on Mar 03, 2021

MDxHealth SA to Report First Half, 2021 Results on Aug 26, 2021

New 90-day high: €1.07

MDxHealth's (EBR:MDXH) Stock Price Has Reduced 75% In The Past Five Years

New 90-day high: €1.00

Is MDxHealth (EBR:MDXH) Weighed On By Its Debt Load?

Price target raised to €1.00

MDxHealth SA Suspends 2020 Guidance

New 90-day low - €0.69

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines